Harvard medical school and ISK Ltd submitted a grant application for a clinical trial with Alzheimer’s patientsApril 13, 2021

ISK Ltd and Harvard medical school submitted together grant application to support phase 1B clinical trial for treatment of Alzheimer’s disease.

13 Apr|

PHASE 1B/2A Clinical trial started

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

13 Apr|

ISK received the FDA’s approval to start Phase 1b/2a with AML patientsJanuary 9, 2020

09 Jan|

Cooperation with Harvard Medical School (MGH)October 27, 2019

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases

27 Oct|

Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK LtdApril 9, 2019

Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John

09 Apr|

ISK attended the 2019 Sachs conference in ZurichMarch 5, 2019

05 Mar|

Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory boardFebruary 25, 2019

Prof. Joseph D Rosenblatt
Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology

25 Feb|

Nerofe has received a new US patent for metastatic cancer treatmentNovember 21, 2018

21 Nov|

Phase2a Nerofe study has begun in Rabin and Kaplan medical centersSeptember 21, 2018

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

21 Sep|

PMWC 2018 conference – New Technology PresentedFebruary 4, 2018

At  PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy” 

04 Feb|